|
For Health Care Professionals
Efficacy
|
Convenience
|
Irritation Profile
|
Microsponge® Technology
An AK Contender
|
Full Prescribing Information
References
Gupta AK, Cooper EA, Feldman SR, et al. A survey of office visits for actinic keratosis
as reported by NAMCS, 1990-1999. Cutis. 2002;70(2S):8-13. Freedberg IM, Eisen AZ, Wolff K, et al, eds. Epithelial precancerous lesions. In:
Fitzpatrick's Dermatology in General Medicine. New York, NY: McGraw Hill Publishing,
2003:723. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma
("actinic keratosis"). J Am Acad Dermatol. 2000;42:S11-17. IMS Data, TRx, year to date, September 2004. Carac® Prescribing Information, Dermik Laboratories, 2003. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5%
fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2S):22-29. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil
formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic
keratosis. Cutis. 2002;70:335-339. Data on file, Dermik Laboratories. A.P. Pharma. Topical technology. Available at: http://www.appharma.com/PDFs/topicalsht.pdf
(Date accessed: April 22, 2005). Efudex® prescribing information. Solaraze® prescribing information. Aldara™ prescribing information.
|
